alytas therapeutics GmbH was founded in 2018 as a spin-off from the University of Jena and is based in Jena, Germany. The founders are experts in lipid-associated metabolic disorders and related comorbidities (such as obesity).

alytas therapeutics GmbH is dedicated to developing new therapeutic targets for the treatment of obesity. The company is currently working closely with the University Hospital Jena (Germany) and CureDiab GmbH in Düsseldorf. Given the current epidemic increase in obesity and the associated comorbidities, there is a high demand for innovative therapies. alytas therapeutics focuses on the sustainable elimination of fat cells relevant to the comorbidities, in combination with weight loss.

For more information, please visit: https://alytas.com/